secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001517022-25-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia posts Q1 2025 net income of $6.1M; Vafseo launch generates $12.0M in net product rev
--------------------------------------------------------------------------------

- Total Q1 2025 net product revenues $55.8M, up 80% YoY; Vafseo contributed $12.0M in first quarter of U.S. launch.
- Net income of $6.1M in Q1 2025 versus net loss of $18.0M in Q1 2024; driven by Vafseo and Auryxia sales.
- Auryxia net revenues $43.8M (up from $31.0M YoY); market exclusivity lost March 20, 2025 but no ANDA approved.
- Cash and equivalents $113.4M as of March 31, 2025, up from $51.9M at Dec 31, 2024, after $50M public offering.
- Plan to initiate Phase 3 VALOR trial for vadadustat in non-dialysis CKD patients in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000027/0001517022-25-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000027/akba-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001517022-25-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer